Brokerages Set Omnicell, Inc. (NASDAQ:OMCL) PT at $42.20

Shares of Omnicell, Inc. (NASDAQ:OMCL) have received an average rating of “Hold” from the six ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $42.20.

A number of brokerages have recently commented on OMCL. Wells Fargo & Company cut their price target on shares of Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a report on Friday, February 9th. Barclays initiated coverage on Omnicell in a research report on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 target price for the company. Finally, Benchmark reduced their price target on Omnicell from $42.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, February 9th.

Omnicell Trading Down 1.1 %

Shares of OMCL stock opened at $27.13 on Tuesday. Omnicell has a twelve month low of $25.69 and a twelve month high of $77.14. The stock’s fifty day simple moving average is $27.68 and its 200 day simple moving average is $32.44. The company has a quick ratio of 2.22, a current ratio of 2.52 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $1.25 billion, a P/E ratio of -60.29 and a beta of 0.76.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. The company had revenue of $258.85 million for the quarter, compared to analysts’ expectations of $256.00 million. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. As a group, sell-side analysts predict that Omnicell will post 0.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Institutional investors have recently added to or reduced their stakes in the business. Horrell Capital Management Inc. increased its stake in shares of Omnicell by 82.0% in the 1st quarter. Horrell Capital Management Inc. now owns 91,000 shares of the company’s stock valued at $2,660,000 after acquiring an additional 41,000 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Omnicell by 2.2% in the first quarter. Assenagon Asset Management S.A. now owns 371,835 shares of the company’s stock worth $10,869,000 after purchasing an additional 8,096 shares during the period. Accurate Wealth Management LLC bought a new stake in Omnicell in the first quarter valued at $364,000. Tributary Capital Management LLC raised its holdings in shares of Omnicell by 4.0% during the first quarter. Tributary Capital Management LLC now owns 315,158 shares of the company’s stock valued at $9,212,000 after purchasing an additional 12,243 shares during the period. Finally, Diversified Trust Co boosted its position in shares of Omnicell by 18.5% during the 1st quarter. Diversified Trust Co now owns 14,870 shares of the company’s stock worth $435,000 after purchasing an additional 2,326 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.